Bad Blood

John Carreyrou, the Wall Street Journal reporter who broke the Theranos story, reconstructs how Elizabeth Holmes built a blood-testing startup valued at nine billion dollars on a device that could not reliably do what she claimed — and how a culture of extreme secrecy, legal intimidation, and founder mythology kept that fact hidden from investors, partners, and patients for years. The book is less a conventional business narrative than a slow-building thriller, following whistleblowers inside the company who risked their careers and faced lawsuits and surveillance to get the truth out.

It matters because Theranos is the starkest modern case study in how Silicon Valley's tolerance for "fake it till you make it" collides catastrophically with an industry — medicine — where faking it can hurt real patients, and because it names, in granular detail, exactly which organizational choices let a fraud of this scale survive as long as it did.

Who should read it

Anyone in health tech, biotech, or regulated industries should treat this as required reading on where startup optimism becomes fraud. It's also a gripping read for anyone interested in whistleblowing, corporate secrecy, or the mechanics of how brilliant, credentialed boards get fooled.

About the author

John Carreyrou is an investigative reporter who spent nearly two decades at the Wall Street Journal, where his reporting on Theranos beginning in 2015 triggered the company's collapse and Holmes's eventual criminal conviction.